NSI-189 nootropic & neurogenic research chemical derived from nicotinamide & pyrazine

FOB Reference Price:Get Latest Price
$10.00 - $15.00 / Gram | 100 Gram/Grams (Min. Order)
Report Suspicious Activity
Overview
Quick Details
CAS No.:
NSI189
Other Names:
NSI-189
MF:
NSI-189 NSI-189 is a nootropic and neurogenic research chemical derive
EINECS No.:
NSI-189
Place of Origin:
Hubei, China
Type:
Anesthetic Agents, Antibiotic and Antimicrobial Agents, Antineoplastic Agents, Antiparasitic Agents, Antipyretic Analgesics and NSAIDs, Central Nervous System Agents, Immune Function Agents, Vitamins, Amino Acids and Coenzymes
Grade Standard:
Food Grade, Medicine Grade
Brand Name:
hhd
Model Number:
hhd
Purity:
99% min
Appearance:
White to light yellow powder
Supply Ability
Supply Ability:
100 Kilogram/Kilograms per Month
Packaging & Delivery
Packaging Details
5g/bag ,10g/bag ,500g/bag, 1kg/tin,25kg/drum
Port
any port

 

NSI-189

 

 

 

NSI-189 is a nootropic and neurogenic research chemical derived from nicotinamide and pyrazine created by Neuralstem, Inc. Research into NSI-189 has been heavily funded by the Defense Advanced Research Projects Agency (DARPA) and theNational Institutes of Health (NIH).

 

 

 

NSA-189 is a proprietary new chemical entity that stimulates new neuron growth in the hippocampus, an area of the brain believed to be contributory in MDD and other conditions, such as Alzheimer’s disease and Post-traumatic stress disorder (PTSD). Phase 1b of the clinical trial is to test the safety and tolerability of the drug in depressed patients.

 

 

Pharmacology

 

NSI-189 has been shown to stimulate neurogenesis of human hippocampus-derived neural stem cells in vitro and in vivo. The hippocampus is responsible for the consolidation of information from short-term memory to long-term memory, along with spatial navigation.

 

NSI-189 has been shown to increase the hippocampal volume of healthy adult mice by 20%.

 

Clinical trials
NSI-189 successfully completed a phase 1 clinical trial in 2011 where it was administered to 41 healthy volunteers, with no adverse effects reported.

 

A phase 1B clinical trial for treating major depressive disorder in 24 patients started in 2012, with study completion expected in January 2014.

 

Assuming positive outcomes in the phase 1b clinical trial, Neuralstem intends to pursue further clinical trials for a variety of encephalopathic conditions including major depressive disorder, traumatic brain injury, Alzheimer's disease, post-traumatic stress disorder, stroke and natural aging.


 

 

 

 

Identification
Name [2-[(3-Methylbutyl)amino]-3-pyridinyl][4-(phenylmethyl)-1-piperazinyl]methanone
 
Molecular Structure 
 
Molecular Formula C22H30N4O
Molecular Weight 366.50
CAS Registry Number 1270138-40-3
   
Properties
 
Solubility Sparingly Soluble (0.070 g/L) (25 ºC), Calc.*
Density 1.134±0.06 g/cm3 (20 ºC 760 Torr), Calc.*

 

 

Other items

 Coluracetam /CAS:135463-81-9

CDP-choline citicoline  cas 987-78-0

Gaba  cas 56-12-2

Huperzine A cas 102518-79-6

L-theanine cas 3081-61-6
Nefiracetam cas 77191-36-7
 N-Methyl-D-aspartic Acid /CAS:6384-92-5
 Noopept/CAS:157115-85-0

Pramiracetam Sulfate /CAS:72869-16-0 

 Sunifiram cas 314728-85-3
 Unifiram cas 272786-64-8
 Vinpocetine cas 42971-09-5

 

 

FOR RESEARCH USE ONLY!

 

name card

 

Nancy Chuang (Market Director)

Wuhan Hengheda Pharm Co., Ltd
Skype: nancy_nan4
Tel: 86-27-84888681  Fax: 86-27-84888682
Phone:86-013419582772(what's app & wechat)